The article analyzes potential NASDAQ stocks for the highest gainer tomorrow, focusing on small-cap stocks below $50 with strong technical indicators. It evaluates companies like Science Applications International (SAIC), Zentalis Pharmaceuticals, and Acme United (ACU), but concludes that no stocks meet all criteria (price below $50, strong momentum, and technical signals). SAIC is identified as overbought and priced above $50, while other stocks lack price data or fail to meet user-specific requirements.

A study explores CRISPR/Cas9 genome editing to disrupt ZBTB7A/LRF and BCL11A binding sites, reactivating fetal hemoglobin in patients with β-thalassemia and sickle cell disease. The research highlights comparable efficacy of both gene edits in boosting γ-globin production while minimizing off-target effects.

The article discusses osteosarcoma, a rare bone cancer affecting children and teenagers, detailing its symptoms, diagnosis, and treatment options. It highlights the FDA's breakthrough therapy designation for GSK5764227 (GSK’227) and outlines 25+ active companies developing 30+ pipeline therapies for osteosarcoma treatment.

Zentalis Pharmaceuticals held its 2025 Annual Meeting of Stockholders, where shareholders elected three Class II directors, ratified Ernst & Young LLP as its independent accounting firm, and approved executive compensation. The company also shared updates on its cancer research, including clinical trial results for azenosertib and analyst ratings. The meeting concluded with all proposed items approved.

Wedbush analyst Robert Driscoll reiterated a 'Neutral' rating for Zentalis Pharma (ZNTL, Financial), maintaining the $4.00 USD price target. The rating reflects a neutral outlook, with no expected short-term stock value changes. The average target price from 9 analysts is $5.97, and the consensus recommendation is 2.4, indicating 'Outperform' status.